A method of making a water-soluble complex comprising an anthracycline or its pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or polymorph by mixing the anthracycline with a non-nutritive sugar and/or surfactant in the presence of a solvent, removing the solvent, and dissolving the water-soluble complex in water. Water-soluble complexes and compositions contained in the complexes are also described.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
in vivo in vitroin vitro, wherein the PSD is idebenone using a non-nutritive sugar or a surfactant, or a surfactant and a non-nutritive sugar in combination that is dissolved in a solvent. Non-nutritive sugars can include rubusoside, rebaudioside A, dulcoside B, dodecyl-β-D-maltoside (DDM), or stevioside.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61K 8/35 - Cétones, p. ex. quinones, benzophénone
A61Q 19/00 - Préparations pour les soins de la peau
3.
COMPOSITIONS AND METHODS FOR IMPROVING THE SOLUBILITY OF INSULIN, INSULIN ANALOGS, AND A1C OR GLUCOSE REGULATORY COMPOUNDS
A method is disclosed for improving the solubility of a drug compound, wherein the drug compound is insulin, a natural insulin variant, an insulin variant, or insulin analog, a GLP-1 agonist, a GIP agonist, a glucagon agonist, an amylin agonist, or an incretin mimetic. The method uses a non-nutritive sugar such as rubusoside, rebaudioside A, dulcoside B, dodecyl-β-D-maltoside (DDM), or stevioside, or any combination thereof in the presence of a solvent such as ethanol or solvent mixtures thereof, and then removing the solvent by drying and solubilizing again to create a water-soluble complex that dissolves in water. Also described are complexes formed using the disclosed methods.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A method is disclosed for improving the solubility of a poorly soluble drug compound such as by mixing the poorly water-soluble drug compound (such as alprostadil, sildenafil, tadalafil, vardenafil, avanafil, or a pharmaceutically acceptable salt of any thereof) with a non-nutritive sugar such as rubusoside, rebaudioside A, dulcoside B, dodecyl-β-D-maltoside (DDM), or stevioside, or any combination thereof in the presence of a pharmaceutically acceptable solvent such as ethanol and then removing the solvent to creating a water-soluble drug-sugar complex.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A method is disclosed for improving the solubility of a poorly soluble drug compound such as by mixing the poorly water-soluble drug compound (such as alprostadil, sildenafil, tadalafil, vardenafil, avanafil, or a pharmaceutically acceptable salt of any thereof) with a non-nutritive sugar such as rubusoside, rebaudioside A, dulcoside B, dodecyl-β-D-maltoside (DDM), or stevioside, or any combination thereof in the presence of a pharmaceutically acceptable solvent such as ethanol and then removing the solvent to creating a water-soluble drug-sugar complex.
A method is disclosed for improving the solubility of a compound by mixing the compound with a non-nutritive sugar in the presence of a solvent and then removing the solvent creating a water-soluble complex of the sugar and the compound rendering the compound to be more soluble in an aqueous solution than the compound had been without the sugar. The compound is a poorly soluble compound or insoluble compound and can be a pharmaceutical compound.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/366 - Lactones ayant des cycles à six chaînons, p. ex. delta-lactones
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A patty with Artemisia and a method for making the patty are described. Also, a nectar with Artemisia and a method for making the nectar are described. In some examples, the Artemisia may include Artemisia annua or Artemisia afra.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A servicing tool may provide a portable, lightweight solution to adjusting the height of struts of aircraft. The tool may provide hydraulic fluid at high pressure to an already pressurized strut. The hydraulic fluid may be supplied to the strut by the tool at a pressure in excess of a pressured gas in the strut to increase the height of the strut. The tool provides techniques to raise and lower the strut when access to high-pressure gas is unavailable. Further, with the application of high-pressure hydraulic fluid, the tool may be used to increase the strut height while also increasing the stiffness of the strut so as to reduce a risk of dynamic rollover.
F04B 49/22 - Commande des "machines", pompes ou installations de pompage ou mesures de sécurité les concernant non prévues dans les groupes ou présentant un intérêt autre que celui visé par ces groupes par clapets
Praziquantel may be formulated to enhance its pharmacokinetic, toxicity, and palatability properties. It can be stored and/or dispensed as a liquid, powder, or tablet. Reduction in the most common side effects improves patient compliance and satisfaction. Altered taste profile improves patient compliance and satisfaction. Once formulated it can be used to treat a variety of blood flukes and worms in human and veterinary subjects.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
Praziquantel may be formulated to enhance its pharmacokinetic, toxicity, and palatability properties. It can be stored and/or dispensed as a liquid, powder, or tablet. Reduction in the most common side effects improves patient compliance and satisfaction. Altered taste profile improves patient compliance and satisfaction. Once formulated it can be used to treat a variety of blood flukes and worms in human and veterinary subjects.
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
Formulations of praziquantel are used to locally treat female genital schistosomiasis. The formulations can be applied to the upper or lower female genital tract, depending on the location of the infection. Thick or viscous formulations can be used advantageously in the vagina. Solutions of active ingredient can be instilled in the uterus.
Formulations of praziquantel are used to locally treat female genital schistosomiasis. The formulations can be applied to the upper or lower female genital tract, depending on the location of the infection. Thick or viscous formulations can be used advantageously in the vagina. Solutions of active ingredient can be instilled in the uterus.
